JP2010519383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519383A5 JP2010519383A5 JP2009550877A JP2009550877A JP2010519383A5 JP 2010519383 A5 JP2010519383 A5 JP 2010519383A5 JP 2009550877 A JP2009550877 A JP 2009550877A JP 2009550877 A JP2009550877 A JP 2009550877A JP 2010519383 A5 JP2010519383 A5 JP 2010519383A5
- Authority
- JP
- Japan
- Prior art keywords
- fucoidan
- composition
- item
- subject
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 47
- 229920000855 Fucoidan Polymers 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 29
- 239000002738 chelating agent Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000023555 blood coagulation Effects 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 241000195480 Fucus Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000356 contaminant Substances 0.000 claims description 4
- 229950007919 egtazic acid Drugs 0.000 claims description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 4
- 206010053567 Coagulopathies Diseases 0.000 claims description 3
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 241001466453 Laminaria Species 0.000 claims description 2
- 241000015177 Saccharina japonica Species 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 230000023597 hemostasis Effects 0.000 claims description 2
- 239000008241 heterogeneous mixture Substances 0.000 claims description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical group OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000002947 procoagulating effect Effects 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims description 2
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 206010063563 Congenital coagulopathy Diseases 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89128707P | 2007-02-23 | 2007-02-23 | |
| US60/891,287 | 2007-02-23 | ||
| PCT/US2008/001425 WO2008103234A1 (en) | 2007-02-23 | 2008-02-01 | Process methods for fucoidan purification from seaweed extracts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519383A JP2010519383A (ja) | 2010-06-03 |
| JP2010519383A5 true JP2010519383A5 (enExample) | 2010-07-15 |
| JP5679663B2 JP5679663B2 (ja) | 2015-03-04 |
Family
ID=39545010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550877A Active JP5679663B2 (ja) | 2007-02-23 | 2008-02-01 | 海藻抽出物からのフコイダン精製のためのプロセスの方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8748595B2 (enExample) |
| EP (3) | EP2121767B1 (enExample) |
| JP (1) | JP5679663B2 (enExample) |
| KR (1) | KR101486931B1 (enExample) |
| CN (2) | CN101663326B (enExample) |
| ES (2) | ES2683948T3 (enExample) |
| WO (1) | WO2008103234A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101663326B (zh) * | 2007-02-23 | 2013-03-20 | 巴克斯特国际公司 | 从海藻提取物中纯化岩藻依聚糖的工艺方法 |
| JP5739816B2 (ja) | 2008-12-19 | 2015-06-24 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | Ｔｆｐｉインヒビターおよび使用法 |
| JO3676B1 (ar) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها |
| CN101659709B (zh) * | 2009-09-18 | 2011-09-07 | 集美大学 | 岩藻聚糖的制备方法 |
| US8632991B2 (en) * | 2010-01-14 | 2014-01-21 | Baxter International Inc. | Methods and compositions for treating bleeding disorders |
| WO2011115712A2 (en) | 2010-03-19 | 2011-09-22 | Baxter International Inc | Tfpi inhibitors and methods of use |
| CN102933192A (zh) * | 2010-05-27 | 2013-02-13 | 勒蒂实验室有限公司 | 用于治疗通过编码角质化包膜成熟缺陷发生的疾病或病症的局部用药物或化妆品组合物 |
| EP2588119A4 (en) * | 2010-06-28 | 2014-01-08 | Stemtech Internat Inc | METHOD AND COMPOSITIONS FOR IMPROVING STRAIN CELL MOBILIZATION |
| EP2643356B1 (en) * | 2010-11-23 | 2021-03-31 | DuPont Nutrition USA, Inc. | Process for isolating fucoidan and laminarin from live, harvested seaweed |
| CN103338780A (zh) * | 2010-12-20 | 2013-10-02 | 韩国食品研究院 | 含有腔昆布提取物和黑昆布提取物的用于正向变构调节gabaa-苯二氮杂*受体的组合物和用于产生镇静催眠效果的组合物 |
| CN102321052B (zh) * | 2011-05-26 | 2013-08-21 | 天津市尖峰天然产物研究开发有限公司 | 综合利用海带提取纯化岩藻黄质和岩藻聚糖硫酸酯的方法 |
| CA2838793C (en) * | 2011-07-19 | 2019-08-06 | Baxter International Inc. | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| US20140186456A1 (en) * | 2011-08-25 | 2014-07-03 | Lillian M. Day | Tripartite Bioactive Composition Providing Anti-Oxidant and Anti-Inflammatory Effects with Immune System and Stem Cell Production Enhancement |
| CN102417549B (zh) * | 2011-11-07 | 2013-07-24 | 沈阳科思高科技有限公司 | 一种基于微波化学的褐藻活性多糖的提取方法 |
| KR20140091674A (ko) | 2011-11-18 | 2014-07-22 | 스템테크 인터내셔널, 인크. | 줄기 세포의 동원 및 증진을 강화하는 foti의 용도 |
| SI2827883T1 (sl) | 2012-03-21 | 2019-08-30 | Baxalta GmbH | Inhibitorji TFPI in postopki uporabe |
| US9417251B2 (en) | 2012-08-14 | 2016-08-16 | Baxalta GmbH | Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides |
| NZ710602A (en) | 2013-01-25 | 2020-01-31 | Marinova Pty Ltd | Methods for reducing pyrogenicity in a seaweed extract |
| CN104698159B (zh) * | 2015-03-10 | 2017-03-08 | 中国科学院苏州生物医学工程技术研究所 | 一种内毒素含量的检测方法 |
| TWI743687B (zh) * | 2016-06-27 | 2021-10-21 | 日商武田藥品工業股份有限公司 | 注射器穩定器 |
| KR101721998B1 (ko) * | 2016-08-16 | 2017-03-31 | (주)한국바이오엔지니어링 | 이미, 이취, 및 염분 제거를 위한 반용매 정제기술이 적용된 후코이단 제조 방법 |
| KR101866906B1 (ko) * | 2017-04-05 | 2018-06-12 | 한남대학교 산학협력단 | 후코이단의 추출방법 |
| CN108641008B (zh) * | 2018-05-11 | 2020-07-24 | 大连工业大学 | 裙带菜孢子叶提取岩藻聚糖硫酸酯及脱除重金属的方法 |
| US12186334B2 (en) | 2018-07-27 | 2025-01-07 | ARC Medical Inc. | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions |
| SG11202100393TA (en) * | 2018-07-27 | 2021-02-25 | Arc Medical Devices Inc | Highly purified fucans for the treatment of fibrous adhesions |
| CN109134680B (zh) * | 2018-09-10 | 2021-03-09 | 深圳华创生物医药科技有限公司 | 一种褐藻糖胶的提取和纯化方法及其应用 |
| GB2579600B (en) | 2018-12-05 | 2023-07-05 | Byotrol Plc | Anti-viral composition |
| MX2021000866A (es) | 2019-03-05 | 2021-06-15 | Arc Medical Devices Inc | Sistemas y metodos para la filtracion de flujo tangencial de composiciones viscosas. |
| RU2717672C1 (ru) * | 2019-04-05 | 2020-03-25 | Гордейчук Владимир Евгеньевич | Способ стимуляции клеток иммунной системы человека |
| SE1950885A1 (en) * | 2019-07-11 | 2021-01-12 | Faelker Knut | Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery |
| KR102309085B1 (ko) | 2019-12-13 | 2021-10-08 | 한국프라임제약주식회사 | 비소가 저감된 해조류 추출물 및 이의 제조방법 |
| EP3932411A1 (en) * | 2020-06-30 | 2022-01-05 | GSK Consumer Healthcare SARL | Antiviral pharmaceutical composition |
| CN112062871B (zh) * | 2020-10-14 | 2022-06-28 | 福州海王福药制药有限公司 | 一种红藻多糖的制备方法 |
| JP7770121B2 (ja) * | 2021-06-30 | 2025-11-14 | ポーラ化成工業株式会社 | ヒアルロン酸受容体発現促進剤、これを含む皮膚外用剤並びに高分子ヒアルロン酸の保持効率向上方法 |
| EP4490042A1 (en) | 2022-03-08 | 2025-01-15 | Equashield Medical Ltd. | Fluid transfer station in a robotic pharmaceutical preparation system |
| CN115386013B (zh) * | 2022-04-19 | 2023-05-12 | 广西中医药大学 | 一种具有强效抗凝活性的海带多糖及其制备方法和应用 |
| EP4590285A1 (en) | 2022-09-21 | 2025-07-30 | Bioatlantis Limited | Phlorotannins and alpha-fucans to treat type 2 diabetes mellitus |
| EP4389251A1 (en) | 2022-12-23 | 2024-06-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods to purify and/or quantify fucoidan |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3275431D1 (en) * | 1981-04-27 | 1987-03-19 | Health Lab Service Board | Affinity chromatography using metal ions |
| JPS6157520A (ja) * | 1984-08-29 | 1986-03-24 | Kibun Food Chemiphar:Kk | フコイダン純度の高い溶液又は、フコイダンの製造方法 |
| JP3714426B2 (ja) | 1994-02-01 | 2005-11-09 | 株式会社糖鎖工学研究所 | フコイダンオリゴ糖組成物含有癌転移抑制剤 |
| CN1150003C (zh) * | 1996-01-26 | 2004-05-19 | 宝酒造株式会社 | 细胞凋亡诱导物 |
| JP3371124B2 (ja) * | 1996-12-24 | 2003-01-27 | 正邦 田幸 | 養殖オキナワモズクを原料とするアセチルフコイダンおよ びそれの製造法 |
| JPH10195106A (ja) * | 1997-01-13 | 1998-07-28 | Masakuni Tako | 養殖イトモズクからの純度の高いフコイダンの製造法 |
| JP4347950B2 (ja) * | 1999-06-14 | 2009-10-21 | 株式会社ヤクルト本社 | 高純度フコイダンおよびその製造方法 |
| US20030039670A1 (en) * | 1999-11-30 | 2003-02-27 | Shigetoshi Mizutani | Cosmetics |
| JPWO2002022140A1 (ja) * | 2000-09-13 | 2004-03-04 | タカラバイオ株式会社 | 恒常性維持剤 |
| JP3676682B2 (ja) * | 2001-01-26 | 2005-07-27 | 株式会社スペース商事 | フコイダン含有抽出物の簡易な製造方法 |
| JP4768142B2 (ja) * | 2001-03-08 | 2011-09-07 | 協同乳業株式会社 | フコイダンの簡易製造方法 |
| CN1173997C (zh) * | 2001-04-28 | 2004-11-03 | 武汉大学 | 高纯度魔芋葡甘聚糖的提取工艺 |
| CN1344565A (zh) * | 2001-10-19 | 2002-04-17 | 汤洁 | 岩藻多糖酯作为抗病毒及免疫调节剂及其制备方法 |
| JP2003155244A (ja) * | 2002-09-13 | 2003-05-27 | Kyodo Milk Industry Co Ltd | モズク由来のフコイダンを含む食品 |
| CN1229393C (zh) * | 2003-01-02 | 2005-11-30 | 合肥学院 | 酶法制备低分子量岩藻多糖工艺 |
| EP1748781B1 (en) | 2004-05-27 | 2012-12-19 | Baxter International Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| CA2571942A1 (en) * | 2004-07-14 | 2006-02-23 | Wyeth | Compositions and methods of purifying myelin-associated glycoprotein (mag) |
| CN101663326B (zh) * | 2007-02-23 | 2013-03-20 | 巴克斯特国际公司 | 从海藻提取物中纯化岩藻依聚糖的工艺方法 |
-
2008
- 2008-02-01 CN CN2008800079552A patent/CN101663326B/zh active Active
- 2008-02-01 US US12/449,712 patent/US8748595B2/en active Active
- 2008-02-01 CN CN201210417761.8A patent/CN102911281B/zh active Active
- 2008-02-01 EP EP08725114.6A patent/EP2121767B1/en active Active
- 2008-02-01 WO PCT/US2008/001425 patent/WO2008103234A1/en not_active Ceased
- 2008-02-01 ES ES12175889.0T patent/ES2683948T3/es active Active
- 2008-02-01 KR KR1020097019831A patent/KR101486931B1/ko active Active
- 2008-02-01 EP EP12175889.0A patent/EP2532686B1/en active Active
- 2008-02-01 ES ES08725114.6T patent/ES2476250T3/es active Active
- 2008-02-01 JP JP2009550877A patent/JP5679663B2/ja active Active
- 2008-02-01 EP EP18172045.9A patent/EP3409694A1/en not_active Withdrawn
-
2014
- 2014-05-01 US US14/267,791 patent/US9234051B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519383A5 (enExample) | ||
| JP5255456B2 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| MA34470B1 (fr) | Procédés et composés pour traiter des infections à virus paramyxoviridae | |
| BRPI0306993B8 (pt) | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível | |
| Maldonado et al. | Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19 | |
| RU2015134583A (ru) | Фармацевтические композиции, содержащие доноры нитроксила | |
| BRPI0915269A2 (pt) | octonidina ou um sal farmacêutico do mesmo, kit farmacêutico, composição farmacêutica e agente farmacêutico | |
| FI2034956T4 (fi) | Matalan viskositeetin omaavia glykosaminoglykaaneja käsittäviä koostumuksia ja mainitun koostumuksen käyttö kroonisen kystiitin terapiassa | |
| WO2022008597A1 (en) | Methods and pharmaceutical composition for the treatment of infectious diseases | |
| JP2010539974A5 (enExample) | ||
| RU2009107068A (ru) | Применение пропиленгликоля при лечении связанных с воспалением местных нарушений или заболеваний и ран | |
| WO2021253008A1 (en) | Partially desulfated heparin for treating coronaviral infections | |
| NO20075758L (no) | Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin | |
| Rizvi et al. | The enigma of sickle cell hepatopathy: Pathophysiology, clinical manifestations and therapy | |
| WO2015142924A1 (en) | Multivalent cation formulations of partially desulfated heparins | |
| JPH0710772A (ja) | 炎症性浮腫亢進抑制剤 | |
| ES2246406T3 (es) | Uso de polisacaridos sobresulfatados como inhibidores del hiv. | |
| WO2025049959A3 (en) | Gene editing systems, compositions, and methods for treatment of vexas syndrome | |
| CA3262238A1 (en) | USE OF MANGANESE-CONTAINING COMPOUNDS TO REDUCE URIC ACID LEVELS IN MAMMALS | |
| WO2007078848A3 (en) | Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid | |
| WO2010111215A4 (en) | Compositions and methods for treatment of hemorrhage | |
| CN101391100A (zh) | 重组人源性硫氧还蛋白用于制备治疗内毒素血症药物的应用 | |
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| KR20120086533A (ko) | 미역포자 유래의 혈전용해용 푸코이단 | |
| Rhee | A review of the possibility of Nafamostat Mesylate in COVID-19 treatment |